The Latest Updates and Pharmacist Perspectives on RET Inhibitors in Non-Small Cell Lung Cancer | PTCE Pharmacy Connect

Educational Objectives

• Review recent clinical updates of RET inhibitors and how they fit into the treatment paradigm for non‒small cell lung cancer
• Identify and manage adverse effects of RET inhibitors to ensure patient safety and improve adherence

 

Faculty

Lauren Ledbetter, PharmD, BCOP

Clinical Pharmacy Specialist, Thoracic Medical Oncology

The James Cancer Hospital at The Ohio State University

Columbus, Ohio

 

Moderator

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA

Clinical Pharmacy Manager

University of Kansas Cancer Center

Division of Hematologic Malignancies & Cellular Therapeutics

 

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hour (0.5 CEU) under the ACPE universal activity number 0290-0000-24-304-H01-P. The activity is available for CE credit through October 31, 2025.

 

This activity is supported by an educational grant from Rigel Pharmaceuticals, Inc.